NeuroSense Therapeutics (NRSN) Operating Income (2021 - 2024)
NeuroSense Therapeutics (NRSN) posted Operating Income of -$1.8 million for Q4 2024, up 15.95% sequentially from -$2.1 million in Q3 2024, and up 42.16% YoY from -$1.2 million in Q1 2024.
NeuroSense Therapeutics (NRSN) Operating Income (2021 - 2024) Analysis & Trends
NeuroSense Therapeutics has reported Operating Income for 4 years, with the latest figure at -$1.8 million in Q4 2024.
- Quarterly Operating Income rose 42.16% year-over-year to -$1.8 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was -$9.9 million (up 17.82% YoY) and the FY2025 annual result came in at -$11.1 million, down 11.95% from the prior year.
- Operating Income climbed to -$1.8 million in Q4 2024 per NRSN's latest filing, from -$2.1 million in the prior quarter.
- Over five years, Operating Income peaked at $957000.0 in Q4 2021 and troughed at -$3.6 million in Q2 2022.
- A 4-year average of -$2.3 million and a median of -$3.0 million in 2023 frame the typical range for Operating Income.
- The sharpest annual moves came in 2023 and 2024: Operating Income slumped 703.67% in 2023, then jumped 42.16% in 2024.
- Over 4 years, Operating Income stood at $957000.0 in 2021, then tumbled by 139.81% to -$381000.0 in 2022, then slumped by 703.67% to -$3.1 million in 2023, then surged by 42.16% to -$1.8 million in 2024.
- According to Business Quant data, Operating Income over the past three periods registered -$1.8 million, -$2.1 million, and -$3.0 million for Q4 2024, Q3 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 133.12 Mn |
| 10 | NeuroSense Therapeutics | 9.68 Mn | 9.47 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -1.77 Mn |
| Sep 30, 2024 | -2.11 Mn |
| Jun 30, 2024 | -3.03 Mn |
| Mar 31, 2024 | -2.99 Mn |
| Dec 31, 2023 | -3.06 Mn |
| Sep 30, 2023 | -2.63 Mn |
| Jun 30, 2023 | -3.37 Mn |
| Mar 31, 2023 | -2.99 Mn |
| Dec 31, 2022 | -381,000.00 |
| Sep 30, 2022 | -3.32 Mn |
| Jun 30, 2022 | -3.59 Mn |
| Mar 31, 2022 | -3.26 Mn |
| Dec 31, 2021 | 957,000.00 |
| Jun 30, 2021 | -951,000.00 |